ES2572387T3 - Compuestos anti-infecciosos - Google Patents

Compuestos anti-infecciosos

Info

Publication number
ES2572387T3
ES2572387T3 ES11711032T ES11711032T ES2572387T3 ES 2572387 T3 ES2572387 T3 ES 2572387T3 ES 11711032 T ES11711032 T ES 11711032T ES 11711032 T ES11711032 T ES 11711032T ES 2572387 T3 ES2572387 T3 ES 2572387T3
Authority
ES
Spain
Prior art keywords
group
heterocyclyl
heteroaryl
cycloalkyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11711032T
Other languages
English (en)
Inventor
Zaesung No
Jaeseung Kim
Priscille Brodin Brodin
Min Jung Seo
Young Mi Kim
Jonathan Cechetto
Heekyoung Jeon
Auguste Genovesio
Saeyeon Lee
Sunhee Kang
Fanny Anne Ewann
Ji Youn Nam
Thierry Christophe
Denis Philippe Cedric Fenistein
Heo Jamung
Jang Jiyeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur Korea
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur Korea filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2572387T3 publication Critical patent/ES2572387T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto que tiene la fórmula general Ib:**Fórmula** en la que X, Y y Z son CH; o es 1; n es 0; m es 0, 1, 2, 3 o 4; A es C>=O; W es NH; R2, cada vez que aparece, se selecciona independientemente entre el grupo que consiste en hidrógeno, halógeno, alquilo C1-C10, cicloalquilo C3-C10, alquenilo C2-C10, cicloalquenilo C3-C10, alquinilo C2-C10, haloalquilo C1-C10, -OH, -OR5, alcoxi C1-C10, cicloalcoxi C3-C10, cicloalquilalcoxi C3-C15, cicloalquilalquilo C3-C15, -CN, -NO2, - NH2, -N(R5)2, -C(O)R5, -C(O)OR5, -C(O)N(R5)2, -SR5,-S(O)R5, -S(O)2R5, -S(O)2N(RS)2, arilo, por ejemplo fenilo, bencilo, heteroarilo y heterociclilo; R3, cada vez que aparece, se selecciona independientemente entre el grupo que consiste en hidrógeno, halógeno, alquilo C1-C10, cicloalquilo C3-C10, hidroxilo, -OR6, -CN, -NO2, -NH2, -N(R6)C(O)R6,-C(O)R6, -C(O)OR6, -C(O)N(R6)2, -S(O)R6, -S(O)2R6, -S(O)2N(R6)2, arilo, por ejemplo fenilo, bencilo, heteroarilo, heterociclilo o dos grupos de R3 están conectados entre sí para hacer anillos cíclicos y heterocíclicos de cinco o seis miembros, R5 y R6, cada vez que aparecen, se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquilo C1-C10, cicloalquilo C3-C10, alquenilo C2-C10, cicloalquenilo C3-C10, alquinilo C2-C10, haloalquilo C1-C10, arilo, por ejemplo fenilo, bencilo, heteroarilo y heterociclilo; R10 es un resto seleccionado entre el grupo que consiste en**Fórmula** en las que m' es 0, 1, 2, 3 o 4 y n' es 0, 1, 2 o 3; R11, cada vez que aparece, se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-C10, cicloalquilo C3-C10, alquenilo C2-C10, cicloalquenilo C3-C10, alquinilo C2-C10, haloalquilo C1-C10, -OH, - OR13, alcoxi C1-C10, cicloalcoxi C3-C10, cicloalquilalcoxi C3-C15, cicloalquilalquilo C3-C15, -NH2, -N(R13)2, -C(O)R13, -COOR13, -C(O)N(R13)2, -S(O)R13, -S(O)2R13, -S(O)2N(R13)2, arilo, por ejemplo fenilo, bencilo, heteroarilo y heterociclilo; R12, cada vez que aparece, se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-C10, cicloalquilo C3-C10, alquenilo C2-C10, cicloalquenilo C3-C10, alquinilo C2-C10, haloalquilo C1-C10, hidroxilo, - OR14, -C(O)R14, -C(O)OR14, -CN, -NO2, -NH2, -N(R14)2, -C(O)N(R14)2, S(O)R14, -S(O)2R14, -S(O)2N(R14)2, arilo, por ejemplo fenilo, bencilo, heteroarilo y heterociclilo; R3, cada vez que aparece, se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-C10, cicloalquilo C3-C10, alquenilo C2-C10, cicloalquenilo C3-C10, alquinilo C2-C10, haloalquilo C1-C10, arilo, por ejemplo fenilo, bencilo, heteroarilo y heterociclilo; y R14, cada vez que aparece, se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-C8 opcionalmente sustituido con al menos un hidroxilo o halógeno; cicloalquilo C3-C7, alquenilo C2-C10, cicloalquenilo C3-C10, alquinilo C2-C10, haloalquilo C1-C10, arilo, por ejemplo fenilo, bencilo, heteroarilo y heterociclilo, y sales farmacéuticamente aceptables del mismo para uso en el tratamiento de una infección bacteriana.
ES11711032T 2010-03-18 2011-03-18 Compuestos anti-infecciosos Active ES2572387T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31511310P 2010-03-18 2010-03-18
US201161440937P 2011-02-09 2011-02-09
PCT/EP2011/001345 WO2011113606A1 (en) 2010-03-18 2011-03-18 Anti-infective compounds

Publications (1)

Publication Number Publication Date
ES2572387T3 true ES2572387T3 (es) 2016-05-31

Family

ID=44021876

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11711032T Active ES2572387T3 (es) 2010-03-18 2011-03-18 Compuestos anti-infecciosos

Country Status (18)

Country Link
US (1) US8865734B2 (es)
EP (1) EP2547678B1 (es)
JP (1) JP5944837B2 (es)
KR (1) KR101732212B1 (es)
CN (1) CN102869661B (es)
AU (1) AU2011229423B2 (es)
BR (1) BR112012023576B1 (es)
CA (1) CA2793086C (es)
ES (1) ES2572387T3 (es)
HK (1) HK1180683A1 (es)
IL (1) IL221940A (es)
MX (1) MX345762B (es)
NZ (1) NZ602311A (es)
PL (1) PL2547678T3 (es)
RU (1) RU2576662C2 (es)
SG (2) SG184073A1 (es)
WO (1) WO2011113606A1 (es)
ZA (1) ZA201206814B (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309238B2 (en) 2009-11-05 2016-04-12 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2575473B1 (en) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2012045729A1 (en) * 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
MX2013014082A (es) 2011-05-30 2014-03-21 Astellas Pharma Inc Compuestos de imidazopiridina.
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
AU2012324517A1 (en) * 2011-10-21 2014-05-22 Torrent Pharmaceuticals Limited Novel substituted imidazopyrimidines as Gpbar1 receptor modulators
US8765959B2 (en) * 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
RU2696278C2 (ru) * 2012-07-18 2019-08-01 Юниверсити Оф Нотр Дам Дю Лак 5,5-гетероароматические противоинфекционные соединения
WO2014021383A1 (ja) * 2012-07-31 2014-02-06 協和発酵キリン株式会社 縮環複素環化合物
US8778964B2 (en) * 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
AU2013353117A1 (en) 2012-11-30 2015-06-04 Astellas Pharma Inc. Imidazopyridine compound
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2914100A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
WO2015009525A1 (en) * 2013-07-17 2015-01-22 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
EP3027615B1 (en) * 2013-08-02 2021-07-21 Institut Pasteur Korea Anti-infective compounds
CN105934435B (zh) 2013-12-06 2019-02-22 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物，其制备，及其放射性标记的衍生物
HUE046273T2 (hu) 2014-02-13 2020-02-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CR20200362A (es) 2014-02-13 2020-10-26 Incyte Corp CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
CA2939793A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
JP2017508810A (ja) 2014-03-21 2017-03-30 バイエル・ファルマ・アクティエンゲゼルシャフト シアノ置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
US20170057958A1 (en) 2014-05-02 2017-03-02 Bayer Pharma Aktiengesellschaft Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
CN103965193B (zh) * 2014-05-30 2016-04-06 浙江司太立制药股份有限公司 N-(苯氧烷基)咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
EP3227287B1 (de) 2014-12-02 2019-08-07 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
UA125171C2 (uk) * 2015-07-02 2022-01-26 Янссен Саєнсиз Айрленд Юсі Антибактеріальні сполуки
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
EP3386979B1 (de) 2015-12-10 2020-07-29 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
CA3007699A1 (en) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3421454B9 (en) * 2016-02-26 2023-08-09 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
ES2963148T3 (es) 2016-04-22 2024-03-25 Incyte Corp Formulaciones de un inhibidor de LSD1
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
EA201990044A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Гетероциклические соединения в качестве антибактериальных средств
WO2017216281A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Uc Heterocyclic compounds as antibacterials
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CN106279123B (zh) * 2016-08-15 2018-09-04 郑州大学 3-(苯磺酰甲基)咪唑并杂环类化合物及其合成方法
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3047980A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
EP3428815A1 (en) 2017-07-11 2019-01-16 Institut Pasteur Docking method based on saturation transfer difference nmr data, and means for its implementation
CN111246848A (zh) 2017-10-05 2020-06-05 快尔生物技术公司 与抗结核药物组合的环稠和的噻唑并2-吡啶酮
JP7319977B2 (ja) 2017-12-06 2023-08-02 リン バイオサイエンス，インコーポレイテッド チューブリン阻害剤
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
CN117903140A (zh) 2018-02-27 2024-04-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP7372255B2 (ja) 2018-03-30 2023-10-31 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109651363B (zh) * 2019-01-03 2020-06-26 东华理工大学 胺甲基化咪唑并[1,2-a]吡啶化合物及制备方法
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021018387A1 (en) 2019-07-30 2021-02-04 Qurient Co., Ltd. Different forms of 6-chloro-2-ethyl-n-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
TW202124379A (zh) * 2019-09-10 2021-07-01 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物
CA3149868A1 (en) 2019-09-13 2021-03-18 Jerome Emile Georges Guillemont Antibacterial compounds
CA3155852A1 (en) 2019-09-30 2021-04-08 Incyte Corporation PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
KR20220075335A (ko) 2019-09-30 2022-06-08 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균 화합물
WO2021063914A1 (en) 2019-09-30 2021-04-08 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
CN114786670A (zh) * 2019-12-20 2022-07-22 奎利恩特有限公司 一种药物口服剂型
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
CN111393435A (zh) * 2020-03-16 2020-07-10 青岛吉澳医药科技有限公司 氮杂吲哚酰胺类化合物及其制备方法和用途
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
WO2022016021A1 (en) 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin
JP2024510478A (ja) 2021-03-16 2024-03-07 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
BR112023018654A2 (pt) 2021-03-17 2023-10-03 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE598759A (es) * 1960-01-04
US3133076A (en) * 1961-04-06 1964-05-12 Simes Phenyl-imidazo(1, 2-a)pyridine-6-car-boxylic acids and their esters
US3105834A (en) * 1961-10-11 1963-10-01 Norwich Pharma Co 2-(5-nitro-2-furyl)-imidazo [1, 2-alpha]-pyridine or-pyrimidine
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
HUP0203739A3 (en) * 1999-10-08 2004-07-28 Gruenenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring, process for their preparation and pharmaceutical compositions containing them
AU2001264932A1 (en) * 2000-05-26 2001-12-11 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US7563788B2 (en) * 2004-03-19 2009-07-21 Pfizer Inc. Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
MX2009006863A (es) * 2006-12-20 2009-08-28 Schering Corp Inhibidores novedosos de c-jun-n-terminal cinasas.
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
JP5412429B2 (ja) * 2007-07-23 2014-02-12 クレストーン・インコーポレーテッド 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物
CN103983627A (zh) 2008-06-17 2014-08-13 韩国巴斯德研究所 作为抗结核病药的吡啶并嘧啶化合物
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US9309238B2 (en) 2009-11-05 2016-04-12 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same

Also Published As

Publication number Publication date
NZ602311A (en) 2014-08-29
BR112012023576A2 (pt) 2020-09-01
JP2013522253A (ja) 2013-06-13
PL2547678T3 (pl) 2016-10-31
US8865734B2 (en) 2014-10-21
HK1180683A1 (zh) 2013-10-25
EP2547678B1 (en) 2016-03-16
EP2547678A1 (en) 2013-01-23
BR112012023576B1 (pt) 2022-08-23
CA2793086C (en) 2018-08-21
MX2012010671A (es) 2013-04-03
SG184073A1 (en) 2012-10-30
AU2011229423A1 (en) 2012-09-27
JP5944837B2 (ja) 2016-07-05
SG10201502109VA (en) 2015-05-28
IL221940A (en) 2017-03-30
AU2011229423B2 (en) 2015-12-10
WO2011113606A1 (en) 2011-09-22
WO2011113606A8 (en) 2012-10-26
CN102869661A (zh) 2013-01-09
KR20130028723A (ko) 2013-03-19
RU2576662C2 (ru) 2016-03-10
CN102869661B (zh) 2015-08-05
RU2012144317A (ru) 2014-04-27
KR101732212B1 (ko) 2017-05-02
ZA201206814B (en) 2016-03-30
US20130065884A1 (en) 2013-03-14
CA2793086A1 (en) 2011-09-22
MX345762B (es) 2017-02-15

Similar Documents

Publication Publication Date Title
ES2572387T3 (es) Compuestos anti-infecciosos
GT200900260A (es) Terapia de convinacion anticoagulante con un compuesto que actua como inhibidor del factor xa
CY1118680T1 (el) Φαρμακευτικη συνθεση
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
MD3224256T2 (ro) Compuși N-((het)arilmetil)-heteroaril-carboxamidici în calitate de inhibitori ai kalikreinei plasmatice
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
NZ751197A (en) Compounds and methods of treating infections
BR112015028879A2 (pt) derivados heterocíclicos
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
CL2011000795A1 (es) Compuestos derivados de n-(1,3,4-tiadiazol-2-il) aril/heteroaril-amida, agonistas del receptor de 1-fosfato de esfingosina; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratammiento de enfermedades autoinmunes, inflamatorias cronicas, rechazo de transplantes, dolor, entre otras.
EA201591166A1 (ru) Ингибиторы аутотаксина
ATE440506T1 (de) Synergismus von gos und polyfructose
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
PE20141307A1 (es) Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2)
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5